Sign In
Buy EGRX
$0.460
+0 (+0%)
At Close: Jun 03, 2026
Eagle Pharmaceuticals Announces Filing of TREAKISYM (bendamustine) Rapid Infusion (“RI”) Liquid Formulation in Japan
06:45am, Monday, 10'th May 2021
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (NASDAQ: EGRX) today announced that TREAKISYM RI (50ml) liquid formulation has been filed with the
Eagle Pharmaceuticals Appoints Former FDA Official and Public Health Expert Dr. Luciana Borio to its Board of Directors
06:50am, Monday, 03'rd May 2021
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced the appointment of Luciana (“Lu”) Borio, MD, to its Board of Di
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (NASDAQ: EGRX) today announced that TREAKISYM ready-to-dilute (“RTD”) (bendamustine hydrochlor
Eagle Pharmaceuticals to Host First Quarter 2021 Financial Results on May 10, 2021
04:30pm, Thursday, 29'th Apr 2021
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2021 first quarter financial resu
Eagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tarriff on Q4 2020 Results - Earnings Call Transcript
04:02pm, Tuesday, 02'nd Mar 2021
Eagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tarriff on Q4 2020 Results - Earnings Call Transcript
Eagle Pharmaceuticals (EGRX) Beats Q4 Earnings Estimates
09:05am, Tuesday, 02'nd Mar 2021
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 323.26% and -0.32%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the sto
Eagle Pharmaceuticals: Q4 Earnings Insights
07:02am, Tuesday, 02'nd Mar 2021
Shares of Eagle Pharmaceuticals (NASDAQ:EGRX) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share increased 100.00% year over year to $0.96, which may not c
Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results and Provides Pipeline Review
06:50am, Tuesday, 02'nd Mar 2021
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced financial results for the three and twelve months ended December 31
Eagle Pharmaceuticals to Host Fourth Quarter and Full Year 2020 Financial Results and Pipeline Review on March 2, 2021
04:30pm, Monday, 22'nd Feb 2021
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2020 fourth quarter and full year
Eagle Pharmaceuticals Receives Additional FDA Questions Regarding Vasopressin; Court Date Set for July 7, 2021 in Vasopressin Trial
06:50am, Tuesday, 02'nd Feb 2021
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has issued a
Eagle Pharmaceuticals Announces Update in Vasopressin Trial; Trial Date Postponed
06:50am, Monday, 01'st Feb 2021
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that, on January 29, 2021, the United States District Court for the
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that, on January 8, 2021, the United States District Court for the
Eagle Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference
04:30pm, Monday, 04'th Jan 2021
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chie
Eagle Pharmaceuticals' Presentation at Piper Sandler 32nd Annual Virtual Healthcare Conference Available for Viewing
06:50am, Monday, 23'rd Nov 2020
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the Company's pre-recorded presentation at the Piper Sandler 3
Eagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tarriff on Q3 2020 Results - Earnings Call Transcript
12:31pm, Monday, 02'nd Nov 2020
Eagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tarriff on Q3 2020 Results - Earnings Call Transcript
